ALPS Medical Breakthroughs ETF

SBIO

市值 US$1.74億

With rising Treasury yields and the Federal Reserve's recent interest rate hike ranking as the likely culprits, the previously hot ALPS Medical Breakthroughs ETF (SBIO) is in the midst of a correction. That pullback, though, may be a buying opportunity.

SBIO is rated Sell due to a significant overvaluation vs. its probability-weighted fair NAV of $37.86, far below the $62.22 market price. Current fund pricing capitalizes on large portions of future biotech success, exposing investors to downside if clinical or commercial outcomes disappoint. Despite credible late-stage pipelines and solid cash runways, dilution risk remains high, with modeled scenarios projecting negative annualized returns.

The ALPS Medical Breakthroughs ETF targets late-stage biotech firms primed for clinical catalysts and acquisition interest. SBIO's methodology requires at least one Phase II/III program and 24 months of cash, reducing dilution risk before key events. Recent acquisitions of top holdings post-August highlight SBIO's ability to capture M&A-driven upside and recycle capital into new prospects.

The biotechnology sector continues to ride a massive wave of medical innovation, and ETFs like the ALPS Medical Breakthroughs ETF (SBIO) appear to be capturing the upside.  SBIO posted a solid 5% gain in August, fueled by positive clinical trial data and an accelerating pace of industry mergers and acquisitions.

If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the ALPS Medical Breakthroughs ETF (SBIO), a passively managed exchange traded fund launched on December 31, 2014.

Sabio Holdings Inc. (SBIO:CA) Q2 2026 Earnings Call Transcript

The Russell 2000 closed at a new record high Friday amid continued upwards momentum for several market indexes. That index, with its focus on small-caps, could prove an intriguing source of investing opportunities, given the right approach.

Geopolitical shocks have pushed family offices to rethink nearly every corner of their portfolios. Infrastructure has emerged as the asset class they trust most right now.

Big Pharma has a $300 billion problem, and biotech developers with promising drugs are becoming the fix. Major drugmakers are spending at a pace not seen since 2019 to replace medicines that will soon lose patent protection.

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the ALPS Medical Breakthroughs ETF (SBIO) is a passively managed exchange traded fund launched on December 31, 2014.